Purpose We conducted a phase III trial to determine whether first-line treatment with
raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome …

Purpose: The aim of this open-label phase II study was to evaluate the activity of raltitrexed
(Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with …

Purpose Malignant pleural mesothelioma (MPM) is a rare disease. Unlike other advanced
cancer types, little is known about patient-reported symptoms or health-related quality of life …

Introduction Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is
increasing in frequency worldwide. Treatment options are limited, and response to …

Background This clinical practice guideline, based on a systematic review, was developed
to determine which chemotherapeutic agents (or combinations of agents) show the highest …

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide.
Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus …

This review summarises the results of previously conducted clinical trials, and subsequently
presents data arising from all phase II–III studies on chemotherapy of malignant pleural …

Background:: A phase III trial in patients with malignant pleural mesothelioma demonstrated
a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin …

PURPOSE: To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin
given in combination, to derive a recommended dose for phase II studies, and to explore its …